Raymond James & Associates cut its position in Amedisys, Inc. (NASDAQ:AMED – Free Report) by 3.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,780 shares of the health services provider’s stock after selling 204 shares during the quarter. Raymond James & Associates’ holdings in Amedisys were worth $529,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in AMED. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Amedisys by 9.2% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 2,397 shares of the health services provider’s stock valued at $413,000 after acquiring an additional 202 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Amedisys by 22.1% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 3,425 shares of the health services provider’s stock worth $590,000 after buying an additional 620 shares during the period. HighTower Advisors LLC increased its holdings in Amedisys by 40.4% in the 1st quarter. HighTower Advisors LLC now owns 7,619 shares of the health services provider’s stock worth $1,310,000 after buying an additional 2,193 shares during the period. Citigroup Inc. increased its holdings in Amedisys by 6.4% in the 1st quarter. Citigroup Inc. now owns 13,268 shares of the health services provider’s stock worth $2,287,000 after buying an additional 803 shares during the period. Finally, Bank of Montreal Can increased its holdings in Amedisys by 17.8% in the 1st quarter. Bank of Montreal Can now owns 4,478 shares of the health services provider’s stock worth $775,000 after buying an additional 678 shares during the period. 95.70% of the stock is currently owned by institutional investors.
Amedisys Trading Up 0.7 %
Shares of NASDAQ:AMED opened at $92.94 on Thursday. The business’s 50 day moving average price is $92.94 and its 200-day moving average price is $89.21. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 1.00. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of 1,327.90, a price-to-earnings-growth ratio of 2.51 and a beta of 0.96. Amedisys, Inc. has a 1 year low of $69.36 and a 1 year high of $106.01.
Analyst Upgrades and Downgrades
Several research firms have commented on AMED. Cantor Fitzgerald upped their price objective on Amedisys from $100.00 to $101.00 and gave the stock a “neutral” rating in a research report on Thursday, September 14th. StockNews.com began coverage on Amedisys in a research report on Wednesday. They issued a “buy” rating on the stock. Finally, TD Cowen upped their price objective on Amedisys from $84.00 to $101.00 and gave the stock a “market perform” rating in a research report on Monday, July 31st. Nine investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $103.55.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Five stocks we like better than Amedisys
- Technology Stocks Explained: Here’s What to Know About Tech
- Investing in large cap stocks: Diving into big caps
- How to Read Stock Charts for Beginners
- Why you can make Vertex Pharmaceuticals a buy on any pullback
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Occidental Petroleum: Another bounce from the buy zone
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.